Last reviewed 2026-04-20 · How we verify

BMS-936558-01

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• Alopecia
• Anaemia
• Fatigue
• Asthenia
• Constipation
• Nausea
• Decreased appetite
• Oedema peripheral
• Arthralgia
• Back pain
• Neuropathy peripheral

Key clinical trials

• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Pan Tumor Rollover Study (PHASE2)
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer (PHASE1)
• A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) (PHASE1)
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (PHASE3)
• Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma (PHASE1)
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BMS-936558-01 CI brief — competitive landscape report
• BMS-936558-01 updates RSS · CI watch RSS
• Bristol-Myers Squibb portfolio CI